{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"RKDA","limit":50},"count":50,"signals":[{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":28,"context":"y required additional funding, or unexpected developments or events, could delay the occurrence of such events or prevent the events described in any such statements from occurring which could have a material adverse effect on our business, financial condition and results of operations. We have a history of significant losses, which we expect to continue, and we may never achieve or maintain profitability. We have incur","filed_date":"2026-03-26","accession":"0001193125-26-126238","full_text":"https://origin.rootz.global/static/filing/0001193125-26-126238.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":100,"match_count":35,"context":"eeting). At the virtual Annual Meeting, we will ask you to consider the following proposals: To elect three (3) Class I directors; To approve, on a nonbinding advisory basis, the compensation of our named executive officers; To ratify the appointment of Deloitte & Touche LLP as our independent registered public accountants for the fiscal year ending December 31, 2025; and To transact such other business that may proper","filed_date":"2025-11-19","accession":"0001193125-25-288164","full_text":"https://origin.rootz.global/static/filing/0001193125-25-288164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":100,"match_count":15,"context":"Shackelford Murray | | | 66 | | | Director | | | Amy Yoder | | | 58 | | | Director | | | Gregory D. Waller | | | 75 | | | Director | | Executive Officers Thomas J. Schaefer was appointed as our Chief Financial Officer in January 2023 and was appointed as our President and Chief Executive Officer in July 2024. Mr. Schaefer is an accomplished finance executive with more than 20 years of investment and corporate fina","filed_date":"2025-04-30","accession":"0000950170-25-061044","full_text":"https://origin.rootz.global/static/filing/0000950170-25-061044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":24,"context":"y required additional funding, or unexpected developments or events, could delay the occurrence of such events or prevent the events described in any such statements from occurring which could have a material adverse effect on our business, financial condition and results of operations. 6 [Table of Contents](#table_contents_for_form_10k) We have a history of significant losses, which we expect to continue, and we may ne","filed_date":"2025-03-25","accession":"0000950170-25-044487","full_text":"https://origin.rootz.global/static/filing/0000950170-25-044487.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"lly vested. (3) These options vest on the earlier of the one-year anniversary of the date of grant and the date of the Companys next annual meeting. (4) These options vest in three equal annual installments, with one-third of the shares subject to the option vesting on each of the first three anniversaries of the date of the award. 18 Non-Employee Director Compensation Policy Cash Compensation Each","filed_date":"2024-05-16","accession":"0000950170-24-060967","full_text":"https://origin.rootz.global/static/filing/0000950170-24-060967.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":100,"match_count":29,"context":"number of shares of common stock that may be issued under the 2015 Plan by 200,000 shares and to increase the annual award limits; To approve, on a nonbinding advisory basis, the compensation of our named executive officers; and To transact such other business that may properly come before the virtual Annual Meeting or any adjournment or postponement thereof. This years annual meeting will be a completely virtual meeti","filed_date":"2024-05-16","accession":"0000950170-24-060967","full_text":"https://origin.rootz.global/static/filing/0000950170-24-060967.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":22,"context":"nnot completely eliminate the risk of accidental contamination from hazardous materials. In the event of such contamination, we may be held liable for significant damages or fines, which could have a material adverse effect on our business and operating results. Most of the licenses we grant to our collaborators to use our proprietary genes in certain crops are exclusive within certain jurisdictions, which limits our li","filed_date":"2024-03-28","accession":"0000950170-24-038176","full_text":"https://origin.rootz.global/static/filing/0000950170-24-038176.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":100,"match_count":31,"context":"nt of Deloitte & Touche LLP as our independent registered public accountants for the fiscal year ending December 31, 2023; • To approve, on a nonbinding advisory basis, the compensation of our named executive officers; and • To transact such other business that may properly come before the Annual Meeting or any adjournment or postponement thereof. Our Board of Directors has fixed the close of business on A","filed_date":"2023-04-25","accession":"0000950170-23-014433","full_text":"https://origin.rootz.global/static/filing/0000950170-23-014433.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ch term in Section 4.1(c). “Liens” means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. {3732559.DOCX:} 3 “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). “Material Permits” shall have the meaning ascribed to such term in Section 3.1(n). “Per Share Purchase Pri","filed_date":"2023-03-03","accession":"0000950170-23-006005","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":100,"match_count":23,"context":"nt of Deloitte & Touche LLP as our independent registered public accountants for the fiscal year ending December 31, 2022; • To approve, on a nonbinding advisory basis, the compensation of our named executive officers; and • To transact such other business that may properly come before the Annual Meeting or any adjournment or postponement thereof. Our Board of Directors has fixed the close of business on A","filed_date":"2022-04-19","accession":"0000950170-22-005802","full_text":"https://origin.rootz.global/static/filing/0000950170-22-005802.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":8,"context":"e able to successfully address the above factors, which could negatively impact our intended business plans and financial statements. Negative press from being in the hemp/cannabis space could have a material adverse effect on our business, financial condition, and results of operations. The hemp plant and the cannabis/marijuana plant are both part of the same cannabis sativa genus/species of plant, except that hemp, by","filed_date":"2022-03-31","accession":"0000950170-22-005253","full_text":"https://origin.rootz.global/static/filing/0000950170-22-005253.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":100,"match_count":26,"context":"of Deloitte& Touche LLP as our independent registered public accountants for the fiscal year ending December31, 2021; | | | | | To approve, on a nonbinding advisory basis, the compensation of our named executive officers | | | | | To vote, on a nonbinding advisory basis, to approve the preferred frequency of holding a stockholder advisory vote on the compensation of our named executive officers; and | | | | |","filed_date":"2021-04-20","accession":"0001564590-21-019590","full_text":"https://origin.rootz.global/static/filing/0001564590-21-019590.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":9,"context":"able future. There is no history upon which to base any assumption as to the likelihood that these operations will prove successful. Negative press from being in the hemp/cannabis space could have a material adverse effect on our business, financial condition, and results of operations. The hemp plant and the cannabis/marijuana plant are both part of the samecannabis sativagenus/species of plant, except that hemp, by d","filed_date":"2021-03-31","accession":"0001564590-21-017118","full_text":"https://origin.rootz.global/static/filing/0001564590-21-017118.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":24,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $3.1925, subject to ad","filed_date":"2021-01-29","accession":"0001564590-21-003281","full_text":"https://origin.rootz.global/static/filing/0001564590-21-003281.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"28 | | 16 | (1) | The option exercise price per share reflects the fair market value per share of our common stock on the date of grant. | | | (2) | These options vest in three equal annual installments on October 30, 2017, 2018, and 2029. | | | (3) | These options are fully vested. | | | (4) | These options vest in three equal annual installments on May 12, 2019, 2020, and 2021. | | | (5)","filed_date":"2020-04-17","accession":"0001564590-20-017258","full_text":"https://origin.rootz.global/static/filing/0001564590-20-017258.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":12,"context":"return the deposit if are unable to fulfil the order, which could adversely affect our results of operations and financial condition. Negative press from being in the hemp/cannabis space could have a material adverse effect on our business, financial condition, and results of operations. The hemp plant and the cannabis/marijuana plant are both part of the samecannabis sativagenus/species of plant, except that hemp, by d","filed_date":"2020-03-25","accession":"0001564590-20-012875","full_text":"https://origin.rootz.global/static/filing/0001564590-20-012875.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"/2028 | | | (1) | The option exercise price per share reflects the fair market value per share of our common stock on the date of grant. | | | (2) | These options vest in three equal annual installments on October 30, 2017, 2018, and 2019. | | 16 | (3) | These options are fully vested. | | | (4) | These options vest on the earlier of the one-year anniversary of the date of grant and the date","filed_date":"2019-04-18","accession":"0001564590-19-012009","full_text":"https://origin.rootz.global/static/filing/0001564590-19-012009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":13,"context":"e ultimately found to have done no wrong. A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We have historically derived a substantial amount of our revenues from a limited number of strategic collaborations, under which we have generated revenues through lice","filed_date":"2019-04-01","accession":"0001564590-19-010452","full_text":"https://origin.rootz.global/static/filing/0001564590-19-010452.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"/2028 | | | (1) | The option exercise price per share reflects the fair market value per share of our common stock on the date of grant. | | | (2) | These options vest in three equal annual installments on October 30, 2017, 2018, and 2019. | | | (3) | These options are fully vested. | | | (4) | These options vest on the earlier of the one-year anniversary of the date of grant and the date of","filed_date":"2019-02-13","accession":"0001564590-19-002838","full_text":"https://origin.rootz.global/static/filing/0001564590-19-002838.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":11,"context":"ltimately found to have done no wrong. 26 A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such a","filed_date":"2018-03-20","accession":"0001564590-18-006338","full_text":"https://origin.rootz.global/static/filing/0001564590-18-006338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":12,"context":"e ultimately found to have done no wrong. A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such a","filed_date":"2017-03-08","accession":"0001564590-17-003724","full_text":"https://origin.rootz.global/static/filing/0001564590-17-003724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":12,"context":"e ultimately found to have done no wrong. A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such a","filed_date":"2016-11-10","accession":"0001564590-16-028976","full_text":"https://origin.rootz.global/static/filing/0001564590-16-028976.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":12,"context":"e ultimately found to have done no wrong. A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such a","filed_date":"2016-08-09","accession":"0001564590-16-023753","full_text":"https://origin.rootz.global/static/filing/0001564590-16-023753.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":12,"context":"e ultimately found to have done no wrong. A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such a","filed_date":"2016-05-10","accession":"0001564590-16-018994","full_text":"https://origin.rootz.global/static/filing/0001564590-16-018994.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":12,"context":"e ultimately found to have done no wrong. A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such a","filed_date":"2016-03-08","accession":"0001564590-16-014230","full_text":"https://origin.rootz.global/static/filing/0001564590-16-014230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":8,"context":"e ultimately found to have done no wrong. A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations. We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such as","filed_date":"2015-11-05","accession":"0001564590-15-009725","full_text":"https://origin.rootz.global/static/filing/0001564590-15-009725.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":8,"context":"ltimately found to have done no wrong. **A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations.** We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such","filed_date":"2015-08-11","accession":"0001193125-15-285644","full_text":"https://origin.rootz.global/static/filing/0001193125-15-285644.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":100,"match_count":8,"context":"ltimately found to have done no wrong. **A significant portion of our revenues to date are from a limited number of strategic collaborations, and the termination of these collaborations would have a material adverse effect on our results of operations.** We derive a substantial amount of our revenues from a limited number of strategic collaborations, under which we generate revenues through licensing arrangements such","filed_date":"2015-06-25","accession":"0001193125-15-233674","full_text":"https://origin.rootz.global/static/filing/0001193125-15-233674.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":98,"match_count":11,"context":"or represented by proxy at the meeting and entitled to vote on the election of directors at the Annual Meeting. Plurality means that the nominees who receive the largest number of votes cast for are elected as directors. | | | | Accordingly, the two nominees receiving the highest number of affirmative votes will be elected as Class II directors to serve until the 2020 Annual Meeting of Stockholders or until their","filed_date":"2017-04-26","accession":"0001564590-17-007330","full_text":"https://origin.rootz.global/static/filing/0001564590-17-007330.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"ation Policy Cash Compensation Each non-employee director receives an annual cash retainer of $30,000 for serving on our Board of Directors. The retainer is payable in arrears in equal quarterly installments, subject to such directors continued service on the last day of the preceding quarter and prorated as necessary to reflect service commencement or termination during the quarter. In addition, eac","filed_date":"2025-11-19","accession":"0001193125-25-288164","full_text":"https://origin.rootz.global/static/filing/0001193125-25-288164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"n stock were granted pursuant to our 2015 Omnibus Equity Incentive Plan. (2) The stock options vested as to 25% of the shares on July 27, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter, such that the award is fully vested on July 1, 2024, subject to the executive officers continued service through each vesting date. (3) The stock options vested as to 25% of the share","filed_date":"2025-04-30","accession":"0000950170-25-061044","full_text":"https://origin.rootz.global/static/filing/0000950170-25-061044.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_concentration","strength":96,"match_count":2,"context":"f our current revenues from government agencies, which are not expected to continue in the future and which may expose us to government audits and potential penalties. We historically have derived a significant portion of our revenues from grants from U.S. government agencies, although such grants were a small portion of our revenues in 2019. Our activities that have been funded by our government grants are subject to audits by U","filed_date":"2020-03-25","accession":"0001564590-20-012875","full_text":"https://origin.rootz.global/static/filing/0001564590-20-012875.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":92,"match_count":9,"context":"or represented by proxy at the meeting and entitled to vote on the election of directors at the Annual Meeting. Plurality means that the nominees who receive the largest number of votes cast for are elected as directors. | | 2 Table of Contents | | Accordingly, the two nominees receiving the highest number of affirmative votes will be elected as Class I directors to serve until the 2019 Annual Meeting of Stockho","filed_date":"2016-04-22","accession":"0001193125-16-551909","full_text":"https://origin.rootz.global/static/filing/0001193125-16-551909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ed. (3) These options vest on the earlier of the one-year anniversary of the date of grant and the date of the Company’s next annual meeting. (4) These options vest in three equal annual installments, with one-third of the shares subject to the option vesting on each of the first three anniversaries of the date of the award. 18 Non-Employee Director Compensation Policy Cash Compensation Each","filed_date":"2023-04-25","accession":"0000950170-23-014433","full_text":"https://origin.rootz.global/static/filing/0000950170-23-014433.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":88,"match_count":6,"context":"nnot completely eliminate the risk of accidental contamination from hazardous materials. In the event of such contamination, we may be held liable for significant damages or fines, which could have a material adverse effect on our business and operating results. Most of the licenses we grant to our collaborators to use our proprietary genes in certain crops are exclusive within certain jurisdictions, which limits our li","filed_date":"2023-03-30","accession":"0000950170-23-011019","full_text":"https://origin.rootz.global/static/filing/0000950170-23-011019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":80,"match_count":10,"context":"aration benefits, are considered deferred compensation not exempt under Section 409A (together, the “Deferred Payments”) will be paid or otherwise provided until Executive has a “separation from service” within the meaning of Section 409A. And for purposes of this Agreement, any reference to “termination of employment,” “termination” or any similar term sha","filed_date":"2024-08-23","accession":"0000950170-24-100065","full_text":"https://origin.rootz.global/static/filing/0000950170-24-100065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"(3) | These options vest on the earlier of the one-year anniversary of the date of grant and the date of the Companys next annual meeting. | | | (4) | These options vest in three equal annual installments on May 12, 2019, 2020, and 2021. | | | (5) | These options vest in three equal annual installments on June 6, 2019, 2020, and 2021. | | | (6) | These options vest on the one-year anniversary","filed_date":"2021-04-20","accession":"0001564590-21-019590","full_text":"https://origin.rootz.global/static/filing/0001564590-21-019590.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"/2027 | | | (1) | The option exercise price per share reflects the fair market value per share of our common stock on the date of grant. | | | (2) | These options vest in three equal annual installments on October 30, 2017, 2018, and 2019, subject to the directors continued service through each vesting date. | | | (3) | These options vest on the earlier of the one-year anniversary of the date","filed_date":"2018-05-17","accession":"0001564590-18-013881","full_text":"https://origin.rootz.global/static/filing/0001564590-18-013881.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":77,"match_count":9,"context":"r is qualified or licensed to do business and is in good standing in each jurisdiction in which it is required to be so qualified, except where failure to be so licensed or qualified would not have a Material Adverse Effect on the Purchased Assets or the Business. Seller does not have or own or control, nor has it owned or controlled, any equity interest or any proprietary interest in any corporation, joint venture, par","filed_date":"2021-05-21","accession":"0001564590-21-029293","full_text":"https://origin.rootz.global/static/filing/0001564590-21-029293.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":77,"match_count":9,"context":"esented by proxy at the meeting and entitled to vote on the election of directors at the virtual Annual Meeting. Plurality means that the nominees who receive the largest number of votes cast for are elected as directors. | | Accordingly, the nominee receiving the highest number of affirmative votes will be elected as Class II director, to serve until the 2023 Annual Meeting of Stockholders or until their respective","filed_date":"2020-04-17","accession":"0001564590-20-017258","full_text":"https://origin.rootz.global/static/filing/0001564590-20-017258.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_concentration","strength":66,"match_count":2,"context":"nt portion of our current revenues from government agencies, which may not continue in the future and which may expose us to government audits and potential penalties. We historically have derived a significant portion of our revenues from grants from U.S. government agencies. Our ability to obtain grants is subject to the availability of funds under applicable government programs and approval of our applications to participate i","filed_date":"2019-04-01","accession":"0001564590-19-010452","full_text":"https://origin.rootz.global/static/filing/0001564590-19-010452.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":66,"match_count":7,"context":"enced changes in our management team, which may cause transition problems in our business. We recently have had significant changes in executive leadership, and more could occur. Rajendra Ketkar was appointed as our President and Chief Executive Officer effective May 2016 and was appointed to our board of directors in June 2016. Previously, Roger Salameh had served as our Interim President and Chief Executive Officer following the","filed_date":"2016-11-10","accession":"0001564590-16-028976","full_text":"https://origin.rootz.global/static/filing/0001564590-16-028976.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":66,"match_count":7,"context":"agement team, which may cause transition problems in our business. We recently have had significant changes in executive leadership, and more could occur. Effective May 23, 2016, Rajendra Ketkar was appointed as our President and Chief Executive Officer, replacing Roger Salameh, who had served as our Interim 38 President and Chief Executive Officer since February 2016. Mr. Salameh was appointed as our Chief Operating Officer in co","filed_date":"2016-08-09","accession":"0001564590-16-023753","full_text":"https://origin.rootz.global/static/filing/0001564590-16-023753.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"2016. | | | (2) | The option exercise price per share reflects the fair market value per share of our common stock on the date of grant. | | | (3) | These options vest in three equal annual installments on May 14, 2016, 2017, and 2018. | | | (4) | As of December 31, 2015, all of the options were fully vested and immediately exercisable. Mr. Wong resigned from our Board effective February 10, 2","filed_date":"2016-04-22","accession":"0001193125-16-551909","full_text":"https://origin.rootz.global/static/filing/0001193125-16-551909.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"strategic_event","strength":63,"match_count":6,"context":"erally fall into the following categories: | | | Large Agricultural Biotechnology, Seed, and Chemical Companies: According to Phillips McDougall, the leading 11 seed and trait companies as a group invested $4.1 billion in seed and trait research and development in 2013. This includes conventional and advanced plant breeding, as well as biotechnology trait development. According to Phillips McDougall, only a limited","filed_date":"2016-03-08","accession":"0001564590-16-014230","full_text":"https://origin.rootz.global/static/filing/0001564590-16-014230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":62,"match_count":4,"context":"litigation or other proceedings could divert management time and attention, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on our financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty.","filed_date":"2025-11-07","accession":"0001193125-25-272375","full_text":"https://origin.rootz.global/static/filing/0001193125-25-272375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":62,"match_count":4,"context":"litigation or other proceedings could divert management time and attention, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on our financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty.","filed_date":"2025-08-14","accession":"0000950170-25-109040","full_text":"https://origin.rootz.global/static/filing/0000950170-25-109040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_factor","strength":62,"match_count":4,"context":"litigation or other proceedings could divert management time and attention, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on our financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty.","filed_date":"2026-08-13","accession":"0001193125-26-349205","full_text":"https://origin.rootz.global/static/filing/0001193125-26-349205.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_concentration","strength":61,"match_count":2,"context":"nt portion of our current revenues from government agencies, which may not continue in the future and which may expose us to government audits and potential penalties. We historically have derived a significant portion of our revenues from grants from U.S. government agencies. Our ability to obtain grants is subject to the availability of funds under applicable government programs and approval of our applications to participate i","filed_date":"2018-03-20","accession":"0001564590-18-006338","full_text":"https://origin.rootz.global/static/filing/0001564590-18-006338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"RKDA","company":"Arcadia Biosciences, Inc.","exchange":"Nasdaq","sector":"Crude Petroleum & Natural Gas","signal_type":"risk_concentration","strength":61,"match_count":2,"context":"nt portion of our current revenues from government agencies, which may not continue in the future and which may expose us to government audits and potential penalties. We historically have derived a significant portion of our revenues from grants from U.S. government agencies. Our ability to obtain grants is subject to the availability of funds under applicable government programs and approval of our applications to participate i","filed_date":"2017-03-08","accession":"0001564590-17-003724","full_text":"https://origin.rootz.global/static/filing/0001564590-17-003724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"fe2505ebb628d62527774aa35ef898f9e7f09fe8d51bc74c700d745b7767ee6b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"503ea381ae3dbcbc742471f3b05b6db52f4c2d9fe952fe872bc43df2e319f467","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":24,"hourly_limit":500,"remaining":476,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}